news Archives - HealthTech Connex

HealthTech Connex Welcomes Derek Norsworthy as New CEO

Nov 7, 2024 | news

We are excited to announce Derek Norsworthy as the new CEO of HealthTech Connex! With a forward-thinking approach to healthcare innovation, Derek brings a wealth of expertise and passion to our leadership team at an exciting time in our growth.

Derek joined HealthTech Connex in May 2024 as Chief Strategy Officer, where he immediately made a significant impact. With a strong background in healthcare operations, technology integration, and patient-centered solutions, Derek has been a trusted advisor to leading organizations across the U.S., helping them adopt innovative technologies that drive better patient outcomes. His deep experience in both clinical settings and medical technology makes him uniquely suited to lead HTC as we continue to thrive and expand.

In Derek’s words: “At HealthTech Connex – advanced healthcare, delivered – is more than just a tagline; it’s a promise. We’re pioneering breakthrough interventions and equipping the healthcare ecosystem with tools to make faster, better decisions. I’m honored to lead HTC toward a healthier future for all.”

Derek’s appointment as CEO represents a pivotal moment in HealthTech Connex’s journey. As we scale our impact across the healthcare industry, his leadership will accelerate our mission to deliver innovative solutions through our Clinical Trials Division, commercial arm, and tools like NeuroCatch®. We are excited to continue pushing the boundaries of healthcare technology, ensuring that we remain at the forefront of industry advancements.

Dr. Ryan D’Arcy, Co-Founder and President/CSO of HealthTech Connex described this next step as “an exciting growth stage for HealthTech Connex, as we continue to drive ahead delivering Advanced Healthcare innovations in brain health and performance to global markets. Derek’s leadership has already been instrumental in numerous recent breakthroughs and will no doubt take us quickly through the next level.”

Kirk Fisher, Co-Founder and current CEO of HealthTech Connex will transition to the role of Chairman where his leadership and vision will remain a cornerstone of our continued success. Kirk has been integral in shaping HTC into the thriving organization it is today, and his ongoing guidance will be crucial as we navigate the next phase.

It’s an exciting new chapter for us as we work together to drive HTC’s growth and success into the future!

Pacific Blue Cross and HealthTech Connex Report Successful Results of Collaborative PoNS Therapy™ Innovation Project

Nov 2, 2023 | news

Photo: A patient using PoNS with physical therapy as part of their treatment protocol.

(See this news release on Pacific Blue Cross)

Vancouver, BC (November 2, 2023) – Pacific Blue Cross (PBC) and HealthTech Connex (HTC) are pleased to announce the successful results of a ground-breaking project, conducted with PoNS Therapy™. The project aimed to reduce long-term disability and improve the quality of life for individuals who sustained traumatic brain injuries.

PBC had contracted HTC to deliver PoNS Therapy to nine PBC plan members with protracted disability related to head injuries. Created by Helius Medical Technologies, Inc. (Nasdaq:HSDT), the PoNS™ (Portable Neuromodulation Stimulator) device sends electrical impulses intra-orally which travel through the cranial nerves to the areas of the brainstem that control balance-related movement and the various associated relay systems in the brain. In clinical studies, this type of neuromodulation has been shown to improve gait and balance in patients.

HTC engaged all three of its divisions to conduct this project. The Surrey Neuroplasticity Clinic delivered the 14-week neuromodulation treatment protocol using the PoNS device, and measured the impacts on gait and balance, the primary clinical indication for this technology. They also measured cognition using the NeuroCatch® Platform (NeuroCatch®) that enables rapid access to an objective assessment of brain health at the point of care. NeuroCatch® uses electroencephalogram (EEG) technology to measure neurophysiological markers of cognition in the brain, called brain vital signs. The Centre for Neurology Studies collected and analyzed the data and released it in a whitepaper, titled “Evaluating the Real-World Impact of PoNS Therapy on Return-to-Work Outcomes in Individuals on Long-Term Disability due to Traumatic Brain Injury.”

The results from the study were exceptional:

1. Impressive Return-to-Work Rates: Five out of nine plan members have returned to work and remained there at the six-month checkpoint or are closing their claims as recovered and work-ready. This shows a remarkable improvement in their quality of life and the ability to resume their daily routines.

2. Substantial Cost Savings: The net savings in long-term disability claim costs for PBC were estimated at $1.6M. By accelerating the recovery and rehabilitation of plan members, the study has reduced the burden of healthcare costs for both PBC and the healthcare system.

3. Improved Overall Health Outcomes: Plan members reported noticeable improvements in balance and gait, lower severity of headaches, better mental health scores, and higher cognitive performance. (See whitepaper for details.) The PoNS device has proven to be a powerful tool for enhancing health outcomes for patients.

“In my 31 years as a physiotherapist, I have never seen clinical results like this,” says Tanja Yardley, Vice President of Clinical Innovation at HealthTech Connex. “Not only did PoNS give these patients their lives back, but it also reduced the financial burden to the insurance provider and brought much-needed technology advancements to the patients who could benefit most. Pacific Blue Cross has set a new standard for innovation in healthcare.”

“Partnering with the Surrey Neuroplasticity Clinic to assist our members experiencing chronic, entrenched balance issues not only resulted in better-than-expected clinical results, but also better than expected return-to-work results,” explains Brenda Hockley, Manager of Rehabilitation & Medical Services, Pacific Blue Cross. “We chose members who sustained a traumatic brain injury as the primary cause of disability, exhibiting signs of vertigo, balance vision, headaches and/or related brain trauma symptoms. Co-morbid mental health conditions were welcomed, with members in receipt of disability benefits longer than two years and plateaued in previous treatment with little to no return-to-work expected outcomes. Five of the nine returned to work full time and remained successfully at work greater than six months to their own occupation, with improvements noted in all nine that participated. On a small sample size, we are encouraged by the results achieved. We are excited to see how this outcome will translate into a larger population, with our unwavering commitment to improve the health and well-being for our members.”

For more information about PoNS Therapy, visit ponstherapy.ca. For more information about HealthTech Connex and its divisions, visit healthtechconnex.com. For more information about this project and the whitepaper, reach out to Tanja Yardley at HealthTech Connex.

About Pacific Blue Cross

Pacific Blue Cross is a Health Benefits Society and British Columbia’s number one health benefits provider. Based in Burnaby, BC, the not-for-profit organization provides health, dental, life, disability and travel coverage for 1 in 3 British Columbians through group benefits and individual plans. As part of its mission to improve health and wellbeing for British Columbians, Pacific Blue Cross proactively supports charitable organizations across the province working to improve health outcomes. More information: pac.bluecross.ca.

About HealthTech Connex

HealthTech Connex connects science and R&D to product breakthroughs utilizing state-of-the-art brain health technology. The team comprises recognized health, science, and business leaders with extensive experience in leveraging healthcare advances fueled by agile partnerships through its headquarters in Surrey, British Columbia. Based on the business model MEASURE, TEST, and TREAT, the company strives to optimize brain health through its three divisions: NeuroCatch Inc., Centre for Neurology Studies, and Surrey Neuroplasticity Clinic. HealthTech Connex is dedicated to deliver translational neuroscience innovations to care sectors and communities worldwide. More information: healthtechconnex.com.

About Helius Medical Technologies, Inc.

Helius Medical Technologies is a leading neurotech company in the medical device field focused on neurologic deficits using orally applied technology platform that amplifies the brain’s ability to engage physiologic compensatory mechanisms and promote neuroplasticity, improving the lives of people dealing with neurologic diseases. The Company’s first commercial product is the Portable Neuromodulation Stimulator. More information: www.heliusmedical.com.

About the PoNS Device and PoNS Therapy

The Portable Neuromodulation Stimulator (“PoNS”) is an innovative, non-implantable, orally applied therapy that delivers neurostimulation through a mouthpiece connected to a controller and it’s used, primarily at home, with physical rehabilitation exercise, to improve balance and gait. The PoNS device, which delivers mild electrical impulses to the tongue, has shown effectiveness in treating gait or balance and a significant reduction in the risk of falling in stroke patients in Canada, where it received authorization for sale in three indications: (i) for use as a short-term treatment (14 weeks) of gait deficit due to mild and moderate symptoms from stroke and is to be used in conjunction with physical therapy; (ii) for use as a short-term treatment (14 weeks) of chronic balance deficit due to mild-to-moderate traumatic brain injury (“mmTBI”) and is to be used in conjunction with physical therapy; and (iii) for use as a short-term treatment (14 weeks) of gait deficit due to mild and moderate symptoms from MS and is to be used in conjunction with physical therapy. More information: www.ponstherapy.com.

-30-

Media contact:

Pacific Blue Cross
mediarelations@pac.bluecross.ca

HealthTech Connex Announces Appointment of Chief Commercial Officer to Lead Expansion into the U.S.

Jun 16, 2022 | news

Reilly to Lead U.S. Rollout of Revolutionary NeuroCatch® Platform That Evaluates Cognitive Brain Function Within Just Six Minutes

(See this news release on Accesswire and Digital Journal.)

Boston, Massachusetts, USA (June 14, 2022) – HealthTech Connex (“HTC”), a leading health technology company specializing in neurotechnology innovations, is pleased to announce the appointment of Terry Reilly to its executive leadership team as Chief Commercial Officer (CCO). Based in Boston, Mass., Reilly will focus on leading the U.S. commercial launch of the company’s NeuroCatch® Platform, with the first HTC U.S. operational office scheduled to open in the Boston Medical Technology cluster in 2023. Reilly will work out of this location and collaborate closely with HTC headquarters in Surrey, BC, Canada, to grow its U.S. team and fully deploy NeuroCatch® across North America.

Reilly brings more than 20 years of senior commercial and marketing leadership in the life sciences, drug discovery, pharmaceutical, and medical devices industries to HTC. In his new role, he will drive HTC’s strategic commercial objectives and integrated commercial architecture and provide global oversight of business development, client services, and sales functions. Before joining HTC, Reilly served as VP of Growth for BioIVT, responsible for building the global commercial strategy and leading global sales, marketing, and commercial services teams in the U.S., Europe, and the Asia Pacific. Throughout his career, he has served in senior leadership roles in sales, client services, and business development. He has extensive experience representing multiple global life sciences products and services, commercial leadership of M&A programs, strategic partnerships, and international commercial and marketing team leadership. His early career included roles focused on commercial development at leading organizations, including Cogstate, Taconic Biosciences, Fuld & Company, and Asterand. Reilly holds a Bachelor’s degree from Michigan State University.

The initial focus of Reilly’s new role with HTC is the U.S. launch of the NeuroCatch® Platform—an industry-leading medical device that offers a rapid, objective evaluation of cognitive brain function within six minutes at the point of care. An accessible, portable cognitive brain scanner, NeuroCatch® consists of EEG electrodes embedded in a mesh cap, which wirelessly interfaces with a custom software platform to deliver results. Clinicians can use it at any point of care in healthcare settings, including clinics, labs, hospitals, sporting venues, schools, military theatres, and remote deployments. It is helpful at any time in the care continuum, from baseline evaluation through ongoing treatment, with immediate and intuitive results to guide clinical and therapeutic decisions. Results are easy to interpret, and ERPs can be compared to prior scan history to distinguish changes over time. NeuroCatch® can be leveraged for a diverse range of health conditions, including brain injuries, neurological diseases, mental health issues, and brain optimization including information processing.

“On behalf of HTC, we are thrilled to welcome Terry Reilly to the senior executive leadership team. His vast experience in the life sciences and medical device industries will be instrumental as we work to align our evolving business and commercial U.S. growth strategy,” said HTC President and Chief Scientific Officer Dr. Ryan D’Arcy. “In this critical role, Terry will help to build integrated commercial strategies and a high-performing culture that will support HTC through its next phase of development and expansion to the U.S.”

The first generation NeuroCatch® is currently deployed to clinical and research centers across Canada and research centers in the U.S. The U.S. product launch will be coordinated for the second generation NeuroCatch® release following a similar expansion plan. The initial target markets will be focused on cutting-edge research in the biotech and pharma fields specializing in brain disorders, diseases, and health optimization.

“HTC is at a critical phase of its growth and evolution as a discovery partner of choice,” said Reilly. “I look forward to bringing my global commercial and marketing leadership experience to support the company’s exciting commercial and U.S. launch strategy and its overall vision to accelerate the enhancement and improvement of brain health lives through better testing and innovation.”

Learn more about HTC and NeuroCatch® online, at https://www.neurocatch.com.

About HealthTech Connex

HealthTech Connex connects science and R&D to product breakthroughs utilizing state-of-the-art brain health technology. The team comprises recognized health, science, and business leaders with extensive experience in leveraging healthcare advances fueled by agile partnerships through its headquarters located in the Health and Technology District in Surrey, British Columbia. The company is focused on delivering translational neuroscience innovations to care sectors and communities worldwide. Its trademark product, the NeuroCatch® Platform, consists of EEG electrodes embedded in a mesh cap. It interfaces with a custom software platform to elicit desired brain responses within just six minutes.

# # #

Media Contact:
Evan White
Evan@EvanWhitePR.com
1-509-995-9105

Cognitive Brain Function in Youth Football Players Can be Impaired by Repetitive “Subconcussive” Head Impacts

Feb 23, 2022 | news

Brain health study shows cognitive brain function in youth football players can be impaired by repetitive “subconcussive” head impacts

(See this news release on EurekAlert and Medical Xpress.)

Sioux Falls, South Dakota, U.S. and Surrey, British Columbia, Canada (February 23, 2022) – Neuroscience researchers at Sanford Research in Sioux Falls, South Dakota, U.S., Simon Fraser University (SFU), and HealthTech Connex Inc. located at the Health and Technology District in Surrey, British Columbia, Canada, have published the latest results of their ongoing multi-year football study examining subconcussive changes in cognitive brain function in male youth football players.

The findings were recently published in the peer-reviewed journal Brain Communications in the advanced articles section, titled: “Subconcussive changes in youth football players: Objective evidence using brain vital signs and instrumented accelerometers.”

The research team monitored the brain vital signs of 15 male youth football players (age 14 or under) in Sioux Falls, South Dakota, during pre- and post-season play who did not sustain a concussion diagnosis during the season.

“Brain vital signs” translates complex brain waves measured using portable electroencephalography (EEG) into simple, fast, user-friendly and intuitive results that provide an objective evaluation of cognitive brain function. Called the ABCs of brain function, brain vital signs track three well-established neural responses for Auditory sensation (using a response called the N100), Basic attention (using a response called the P300), and Cognitive processing (using a response called the N400).

The study examined this group of male youth football players and reported cognitive processing sensitivity (N400) to subconcussive impairments in those players who did not sustain a concussion diagnosis over the course of the season. In addition, changes in brain vital signs were highly related to the number of head impacts that the players were exposed to during the season.

This youth football study replicated and built on previous Junior-A and Bantam youth ice hockey concussion and subconcussion study results published in Brain: A Journal of Neurology and Brain Communications which resulted in the same findings, confirming significant brain vitals sign changes and concussive/subconcussive impairments in youth contact sport that went undetected using current clinical concussion protocols.

“By monitoring brain vital signs, extracted from complex brain waves measured using portable electroencephalography (EEG), it was possible for us to track three well-established neural responses for auditory sensation, basic attention, and cognitive processing in these youth football players,” says Dr. Thayne Munce, the study’s principal investigator and Assistant Scientist in the Environmental Influences on Health and Disease Group at Sanford Research. “The results of the study show that repetitive subconcussive impacts triggered compounding effects in brain function changes over time. While more research needs to be done in this area, this is the first step in how we can look at youth contact sports in the future.”

The results of this youth football Brain Communications study showed:

Significant brain vital sign changes in pre-to-post season cognitive processing speed.
A significant relationship between the subconcussive brain vital sign changes and head impact exposures as measured by the total number of head impacts as well as number of games and/or practices over the season.
The authors noted that the brain vital sign changes and total number of head impacts for the football players closely related with the results from older, Junior-A, ice hockey players from a previous study.

Canadian collaborators include neuroscientist Dr. Shaun Fickling, lead R&D scientist at HealthTech Connex Inc., SFU PhD graduate and lead author of the study, as well as Dr. Ryan C. N. D’Arcy, an SFU professor and co-founder of HealthTech Connex Inc. and the Health and Technology District in Surrey B.C. HealthTech Connex Inc. is a health technology company developing the NeuroCatch® Platform.

“These findings provide further support that there is a predictive relationship between head impact exposure in contact sport and subtle changes in cognitive brain function” reports Dr. Shaun Fickling, who was the study’s lead author as part of his PhD in Biomedical Engineering at Simon Fraser University.

“The results are really quite positive and optimistic for the future of brain injury prevention and management in sport,” further explains Dr. Thayne Munce. “Now that we can sensitively detect changes associated with subconcussive impacts, it is possible to identify the leading ways to prevent, treat, and manage possible impairments, which is a critical step that is now getting underway.”

The US-Canadian concussion research collaborators are continuing to utilize these brain vital sign advances to evaluate possible leading innovations in prevention and treatment.

The research study was designed and carried out by investigators at Sanford Research, and partially supported by a grant from the T. Denny Sanford Pediatric Collaborative Research Fund. This project was also supported in part by the Simon Fraser University Graduate International Travel and Research Award (GIRTA).

About Sanford Health:

Sanford Health, one of the largest health systems in the United States, is dedicated to the integrated delivery of health care, genomic medicine, senior care and services, global clinics, research and affordable insurance. Headquartered in Sioux Falls, South Dakota, the organization includes 46 hospitals, 1,500 physicians and more than 200 Good Samaritan Society senior care locations in 26 states and 10 countries. Learn more about Sanford Health’s transformative work to improve the human condition at sanfordhealth.org or Sanford Health News.

About Simon Fraser University (SFU):

As Canada’s engaged university, SFU works with communities, organizations and partners to create, share and embrace knowledge that improves life and generates real change. We deliver a world-class education with lifelong value that shapes change-makers, visionaries and problem-solvers. We connect research and innovation to entrepreneurship and industry to deliver sustainable, relevant solutions to today’s problems. With campuses in British Columbia’s three largest cities—Vancouver, Burnaby and Surrey—SFU has eight faculties that deliver 193 undergraduate degree programs and 127 graduate degree programs to more than 37,000 students. The university now boasts more than 165,000 alumni residing in 143 countries. www.sfu.ca

About HealthTech Connex Inc.:

Located in the Health and Technology District, HealthTech Connex Inc. (HTC) is a brain technology company focusing on cutting-edge innovations and services for rapid impact on health improvements and outcomes in neurological performance. With brain vitality as a premier focus, HealthTech Connex provides translational neuroscience innovations to care and community sectors worldwide, bridging the gap between what is capable in the laboratory and what’s available in the real world. www.healthtechconnex.com

-30-

Media contact:

Yvonne Chiang, news@chiangpr.ca

Neuroscience Researchers Find Repetitive Head Impacts Can Result in Functional Brain Impairments in Youth Hockey

Apr 22, 2021 | news

Photo: Hockey player gets his brain vital signs checked. Researchers find repetitive head impacts can result in functional brain impairments in youth hockey.

Brain Vital Signs Concussion Study in Bantam and Junior A Ice-Hockey Detects Significant Subconcussive Changes in Cognitive Brain Function

(See this news release on EurekAlert and CNW/Cision.)

Surrey, B.C. Canada and Rochester, Minn., U.S. (April 22, 2021) – Neuroscience researchers at Mayo Clinic Orthopedics and Sports Medicine in Rochester, Minnesota, U.S., the Health and Technology District and Simon Fraser University (SFU) in Surrey, British Columbia, Canada have published the latest results of their ongoing multi-year hockey concussion study examining changes in subconcussive cognitive brain function in male youth ice hockey players.

The research team monitored brain vital signs during pre- and post-season play in 23 Bantam (age 14 or under) and Junior A (age 16 to 20) male ice-hockey players in Rochester, Minnesota.

“Brain vital signs” translates complex brain waves measured using portable electroencephalography (EEG) at the rink-side, into simple, fast, user-friendly and intuitive results that provide an objective evaluation of cognitive brain function. Called the ABCs of brain function, brain vital signs track three well-established neural responses for Auditory sensation (using a response called the N100), Basic attention (using a response called the P300), and Cognitive processing (using a response called the N400).

The study builds on 2019 results published in Brain: A Journal of Neurology that confirmed significant brain vitals sign changes shortly after concussions were diagnosed in Junior A players. Key results of this study showed undetected impairments remained when players were cleared to return to play using current clinical concussion protocols. Notably, the initial study also reported sensitivity to subconcussive impairments in those players who did not sustain a concussion diagnosis over the course of the season.

The current second phase of the study replicated these results and added the Bantam age group. The latest findings were recently published in the peer-reviewed journal Brain Communications in the advanced articles section.

The results of this new Brain Communications study showed:

Significant brain vital sign changes in N100 Auditory sensation and N400 Cognitive processing responses for the pre-to-post season comparison across both groups.
Differences between the Bantam and Junior A ice hockey players showed more changes in the Junior A group.
Importantly, the subconcussive changes were significantly correlated with the number of head impacts over the season across both age groups and consequently showed more subconcussive changes in brain vital signs.

A subconcussive impact is a mechanical force transmitted to the brain below the threshold for a diagnosis of an acute concussive injury. The effects of these low-magnitude impacts may not even be noticeable to the player or to observers on the sideline. Head impacts in the sport of ice hockey typically result from player-to-player or player-to-boards contact due to body checking, collisions and fighting[i]. Some of these impacts are the consequence of foul play, but many of these events also result from routine, legal on-ice behavior.

“Concussion in sports is a major concern for many and our research has shown that having an objective physiological measure of brain function at rink-side is key to detection and managing concussive impacts,” says Dr. Aynsley Smith, principal investigator of the study and Associate Professor of Orthopedics at Mayo Clinic in Rochester, Minnesota.

The study, funded in part by USA Hockey, was co-led by Dr. Michael Stuart, Professor of Orthopedics at Mayo Clinic in Rochester, Minnesota. It is also part of a larger concussion research team within Mayo Clinic that includes neurology research leadership from Dr. David Dodick, Professor of Neurology at Mayo Clinic in Phoenix, Arizona, U.S.

Canadian collaborators include neuroscientist Dr. Ryan C. N. D’Arcy, an SFU professor and co-founder of the Health and Technology District in Surrey B.C. and Dr. Shaun Fickling, a biomedical engineer, a recent SFU PhD graduate and lead author of the study.

“Our research has shown that repetitive subconcussive impacts triggered compounding effects in brain function changes, which underscores the importance of shifting our thinking and understanding of concussions as a singular acute-injury model to a spectrum of head-impact exposure and effects over time,” says Dr. Fickling.

The US-Canadian concussion research team is continuing to advance their collaborative effort.

Says Dr. D’Arcy, “In medicine: you can’t treat what you can’t measure. With breakthroughs on measurement challenges, we hope to now accelerate treatment innovations for prevention, acute care and extended care concussion management – for all people across a range of different applications. Our partnership is moving into incredibly exciting future steps – stay tuned.”

The research study was designed and carried out by the Mayo Clinic Sports Medicine Ice Hockey Research team, partially funded by USA Hockey Foundation and the Johannson-Gund Endowment. Financial support was also provided by the Mathematics of Information Technology and Complex Systems (MITACS), Natural Sciences and Engineering Council Canada (NSERC) and the Canadian Institutes for Health Research (CIHR).

About Mayo Clinic

Mayo Clinic is a nonprofit organization committed to innovation in clinical practice, education and research, and providing compassion, expertise and answers to everyone who needs healing. Visit the Mayo Clinic News Network for additional Mayo Clinic news. For information on COVID-19, including Mayo Clinic’s Coronavirus Map tracking tool, which has 14-day forecasting on COVID-19 trends, visit the Mayo Clinic COVID-19 Resource Center.

About Simon Fraser University (SFU)

About the Health and Technology District (the DISTRICT)

The Health and Technology District in Surrey, B.C., is a rapidly expanding ecosystem of innovators and entrepreneurs collaborating with tech companies, scientists, educators and health professionals; each representing a range of business, technologies and research fields. The series of high-tech buildings located and under expansion strategically across from Surrey Memorial Hospital, offers a dynamic community where disruptive impacts are generated through the translation of research, science and technology into global innovations. Within this, the current research is a result of the BrainNET initiative to translate neuroscience knowledge directly into clinical advances in care. www.HealthandTechnologyDistrict.com

[i] Smith AM, Farrell KJ, Roberts WO, Moris MR, Stuart MJ. Eliminating Fighting and Head Hits from Hockey: Opportunities and Barriers. Curr Sports Med Rep 2019; 18: 35–40.

-30-

Media contact:

Yvonne Chiang, 604-880-5090, news@chiangpr.ca

COVID-19 Update

Apr 19, 2021 | news

April 19, 2021

For the past few weeks, at HealthTech Connex we have been closely monitoring the third wave spread of COVID-19 and have been following guidance from the Canadian Public Health Agency and the BC Center for Disease Control.

As the  COVID-19 situation has evolved, we have adapted our digital health products and services to ensure the best for the health and safety of our staff and the communities that we serve.

Our team members remain available during regular business hours by phone (1-604-639-9057) to assist with any inquiries or support requests.

Let’s all do our part to help by following all necessary measures as directed by our Public Health Officials.

Thank you for your patience, understanding and trust in HealthTech Connex.

Take care,

The HealthTech Connex team

« Older Entries